Long Term Extension Study in Patients With Primary Hyperoxaluria

Clinical trial NCT04042402 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT04042402
Sponsor: Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Primary Hyperoxaluria Type 1 (PH1)Primary Hyperoxaluria Type 2 (PH2)Kidney Diseases Urologic Diseases Genetic Disease Primary Hyperoxaluria Type 3 (PH3)

Start date: 2019-07-09
Primary completion: 2030-04-01
Enrollment: 75

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.